Eli Lilly agreed to pay Insilico Medicine $115 million upfront and structured the deal for up to about $2.75 billion in additional payments tied to development, regulatory and commercial milestones, Insilico said. The collaboration expands their three-year AI discovery and development partnership and is focused on preclinical oral therapeutics in unspecified indications. Insilico will grant Lilly an exclusive global license to develop, manufacture and commercialize selected programs from Insilico’s preclinical pipeline, according to the companies’ announcements. The latest terms build on earlier Lilly access to Insilico’s Pharma.AI platform and follow an expansion toward a fuller AI-based drug development partnership announced last year. The agreement underscores Lilly’s continued investment in AI-led discovery outsourcing while preserving upside through milestone-based economics. It also increases commercializing leverage for Insilico, which recently expanded its financing options as an AI-first biotech developer.